Sanofi forms drug discovery pact with French startup Aqemia en route to ‘AI at scale’ ambition
Sanofi CEO Paul Hudson has been clear about his company’s bets on drug discovery’s hottest technology — touting plans to be the “first pharma company powered by artificial intelligence at scale” — and it has now lined up another pact to get there.
The French pharma giant will pay up to $140 million to Paris-based Aqemia as part of a multi-year collaboration to create small molecules for more than one therapeutic area. Further details on the upfront breakdown, timeline and specific disease areas were kept under wraps.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.